The VIPER Paradigm and the Future of Programmable Immunotherapy in Next-Gen CAR T-Cells

1. Introduction: The Exigency of Control in Adoptive Cell Immunotherapy

The clinical ascendancy of Chimeric Antigen Receptor (CAR) T-cell therapy stands as one of the most significant milestones in the history of oncology. By genetically modifying a patient’s own T-lymphocytes to express synthetic receptors—chimeras of monoclonal antibody specificity and T-cell signaling potency—science has delivered a "living drug" capable of eradicating refractory hematological malignancies. The approval of CD19-targeted therapies for acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) validated the premise that the immune system, when adequately redirected, possesses the potency to clear giga-scale tumor burdens.¹

However, the very attribute that grants CAR T-cells their curative potential—their ability to autonomously expand, persist, and execute cytotoxic programs—constitutes their most significant liability. Unlike small molecule drugs or biologics, whose pharmacokinetics (PK) and pharmacodynamics (PD) follow predictable decay curves dictated by metabolic clearance, CAR T-cells are dynamic agents. Upon infusion, they encounter their cognate antigen, undergo rapid proliferation (up to 10,000-fold expansion), and unleash a storm of inflammatory cytokines. This "living" pharmacokinetic profile is often uncoupled from clinical intervention once the infusion is complete.

The consequences of this lack of control are well-documented and occasionally catastrophic. Cytokine Release Syndrome (CRS), driven by the mass activation of T-cells and bystander macrophages, leads to systemic inflammation, hypotension, and multi-organ failure. Neurotoxicity, or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), presents a distinct, poorly understood pathology that can cause cerebral edema and death. Furthermore, the phenomenon of "on-target, off-tumor" toxicity—where CAR T-cells attack healthy tissues expressing low levels of the target antigen—limits the application of this modality in solid tumors, where tumor-restricted antigens are scarce.⁴

Consequently, the frontier of synthetic immunology has shifted from merely enhancing potency to engineering controllability. The field seeks a "remote control" for T-cells—a mechanism to tune their activity in real-time, analogous to adjusting the dosage of a pharmaceutical. It is within this context that the laboratory of Professor Wilson Wong at Boston University developed the VIPER (Versatile Protease Regulatable) CAR T-cell platform. Published in Cancer Cell in 2022, the VIPER system represents a paradigm shift, utilizing viral proteases and FDA-approved antiviral drugs to create a high-performance, reversible, and multiplexable control switch.¹

This report provides an exhaustive analysis of the VIPER technology. We will dissect its molecular architecture, exploring how the Hepatitis C Virus (HCV) NS3 protease—a viral machine evolved for protein processing—was repurposed as a safety switch. We will examine the pharmacological gating using drugs like grazoprevir, benchmark the system against competing technologies, and clarify the distinction between the academic VIPER platform and the clinical-stage products from Vittoria Biotherapeutics (VIPER-101).

2. The Theoretical Framework: From Suicide Genes to Rheostats

To appreciate the innovation of VIPER, one must understand the landscape of "safety switches" that preceded it. The evolution of controllable CARs can be categorized into three generations of control strategies: elimination, repression, and regulation.

2.1 First Generation: The Kill Switch

The earliest attempt to control aberrant T-cell activity was the implementation of "suicide genes." The most prominent example is inducible Caspase-9 (iCasp9). In this system, T-cells are engineered to express a fused Caspase-9 domain that dimerizes in the presence of a small molecule (rimiducid). Dimerization triggers apoptosis, rapidly killing the CAR T-cells. While effective at halting toxicity, this approach is binary and irreversible. It terminates the therapy entirely, discarding the expensive, patient-specific product and leaving the patient vulnerable to tumor relapse. It is a "fire extinguisher" rather than a thermostat.⁷

2.2 Second Generation: Destabilizing Domains and Repression

The second generation sought reversibility. Systems utilizing Destabilizing Domains (DDs) fused to the CAR were developed. These domains are inherently unstable and target the fusion protein for proteasomal degradation unless a stabilizing ligand (e.g., trimethoprim) is present. Conversely, some systems use drugs to disrupt protein signaling. While promising, these systems often suffer from "leakiness" (basal activity in the absence of the drug) or slow kinetics (relying on natural protein turnover rates). The dynamic range—the ratio of activity between the ON and OFF states—was often insufficient for clinical safety, where even a small number of active CARs can drive toxicity.³

2.3 Third Generation: The Enzymatic Switch (VIPER)

The VIPER system introduces a third generation of control: enzymatic regulation. Instead of relying on passive degradation or steric hindrance, VIPER integrates an active enzyme—a protease—directly into the CAR architecture.

The conceptual leap made by Li, Wong, and colleagues was to utilize the efficiency of viral biology. Viruses like Hepatitis C produce their proteins as a single massive polyprotein, which is then sliced into functional units by a viral protease (NS3). This process is rapid, highly specific, and essential for the virus. By transplanting this proteolytic machinery into a CAR, the researchers created a receptor that is "programmed to self-destruct" (or self-cleave) at the protein level unless inhibited by a drug. This mechanism offers superior kinetics because proteolysis is an active, catalytic process, not a passive one.¹

3. Molecular Architecture of VIPER CARs

The core innovation of the VIPER system lies in the precise structural integration of the HCV NS3 protease domain within the chimeric antigen receptor polypeptide. This section details the bioengineering principles governing this design.

3.1 The HCV NS3 Protease Domain

The Non-Structural protein 3 (NS3) of the Hepatitis C Virus is a serine protease. In the viral lifecycle, it associates with a cofactor, NS4A, to cleave the viral polyprotein at specific junctions (NS3/4A, NS4A/4B, NS4B/5A, and NS5A/5B).

• Specificity: The protease recognizes a specific amino acid sequence (e.g., D-E-D-V-V-C-C-S-M-S-Y for the NS5A/5B junction). This high specificity is crucial for synthetic biology; the protease must cleave the engineered sites in the CAR without indiscriminately digesting native host proteins, which would be cytotoxic.¹

• The "Cis" Activity: A unique feature of NS3 is its ability to cleave in cis—meaning it can cleave the polypeptide chain of which it is a part. This is the mechanism exploited in the ON-VIPER CAR.

3.2 The ON-Switch Design: Drug-Dependent Stabilization

The "ON" switch configuration is the most clinically relevant design for safety, as the default state (without drug) is OFF.

3.2.1 Structural Layout

In the ON-VIPER CAR, the NS3 protease domain is inserted into the intracellular signaling tail of the CAR. The typical architecture, moving from the extracellular to intracellular side, is:

1. scFv: Antigen-binding domain (e.g., anti-CD19).

2. Transmembrane Domain: Anchors the receptor.

3. Costimulatory Domain: (e.g., CD28 or 4-1BB).

4. NS3 Protease: The viral enzyme, flanked by cleavage sites.

5. Signaling Domain: CD3ζ (the primary activator).

The cleavage sites (e.g., NS5A/5B) are engineered at the junctions between the protease and the signaling domains.²

3.2.2 Mechanism of Action

• State 0 (No Drug): Upon translation by the ribosome, the CAR polypeptide folds. The integrated NS3 protease immediately recognizes the flanking cleavage sites. It executes a cis-cleavage event. This severs the CD3ζ domain and/or the costimulatory domain from the membrane-anchored portion of the CAR. The signaling tail is released into the cytoplasm and degraded or rendered non-functional. The T-cell remains active-competent but lacks a functional receptor. It is effectively "blind" or "disconnected."

• State 1 (Plus Drug): The patient receives a protease inhibitor (e.g., Grazoprevir). The drug molecule enters the T-cell and binds tightly to the active site of the NS3 domain within the CAR. This binding sterically blocks the catalytic triad of the protease. Consequently, cleavage is inhibited. The CAR remains as a full-length, intact polypeptide. It traffics to the cell surface, where it can bind tumor antigens and transmit signals through the now-tethered CD3ζ domain, triggering T-cell activation.³

This "default-OFF" mechanism is a critical safety feature. If the patient misses a dose, or if the drug supply is interrupted, the system fails safely: the T-cells deactivate. This contrasts with "default-ON" systems where drug withdrawal would leave the cells permanently active.⁴

3.3 The OFF-Switch Design: Drug-Induced Disruption

The researchers also engineered an "OFF" switch, useful for scenarios where constitutive activity is preferred but a pause capability is needed.

The OFF-VIPER system utilizes a different topological arrangement or integrates with the SUPRA (Split, Universal, and Programmable) CAR system. In one variation, the NS3 protease is used to regulate a specific "retention" or "degradation" signal. However, the most robust OFF-switch described in the broader VIPER/SUPRA context often involves using the drug to displace a component.

• Mechanism: In the OFF configuration, the system might employ a split CAR where the two halves (antigen binding and signaling) are held together by a high-affinity interaction involving the NS3 domain (perhaps a mutated version that binds but doesn't cleave a substrate). The addition of the drug competes for the binding site, disrupting the interaction between the two halves of the CAR. The two components dissociate, breaking the signaling chain.⁵

• Performance: The OFF-VIPER CAR demonstrated the ability to be active by default and rapidly suppressed upon Grazoprevir administration. Crucially, this suppression was reversible; washing out the drug restored function.⁵

3.4 Benchmarking vs. Other Systems

To validate the VIPER platform, the Boston University team performed head-to-head comparisons with existing drug-gated systems.

Table 1: Comparison of Inducible CAR Architectures

Feature	VIPER (ON-Switch)	Destabilizing Domain (DD-CAR)	Lenalidomide-Gated (Len-CAR)	SynNotch
Control Mechanism	Proteolytic Cleavage (Enzymatic)	Proteasomal Degradation (Metabolic)	Dimerization (E3 Ligase recruitment)	Transcriptional Regulation
Drug	Grazoprevir (Antiviral)	Trimethoprim (Antibiotic)	Lenalidomide (IMiD)	Not applicable (Cell-Cell)
Response Speed	Fast (Direct protein stabilization)	Slow (Requires synthesis/degradation)	Fast (Dimerization)	Slow (Transcription/Translation)
Basal Leakiness	Very Low (Active self-cleavage)	Moderate (Residual stability)	Low	Low
Dynamic Range	High (>200 fold)	Low/Moderate (~10-20 fold)	High	High
Orthogonality	Yes (Can combine with Len-CAR)	Yes	Yes	Yes
Immunogenicity	High (Viral Protein)	Moderate (Mutant human/bacterial)	Low (Human components)	High (Non-human domains)

The study concluded that ON-VIPER CARs demonstrated "best-in-class" performance, particularly regarding the dynamic range and the tightness of the OFF state compared to the DD-CARs.⁴

4. Pharmacological Gating: Repurposing the Hepatitis C Arsenal

A defining feature of the VIPER system is its reliance on clinically approved antiviral drugs. This strategy, known as drug repurposing, significantly de-risks the path to translation.

4.1 The Drug: Grazoprevir (GZV)

The primary small molecule used to gate VIPER CARs is Grazoprevir.

• Origin: Developed by Merck as part of the Zepatier combination therapy for chronic Hepatitis C genotypes 1 and 4.

• Mechanism: It is a macrocyclic inhibitor of the HCV NS3/4A protease. It binds non-covalently but with extremely high affinity (pM to nM range) to the active site of the enzyme.

• Pharmacokinetics: In humans, Grazoprevir is orally bioavailable with a half-life of approximately 31 hours, allowing for once-daily dosing. It accumulates in the liver but also distributes to other tissues.⁴

4.2 Why Repurposed Antivirals?

1. Safety Profile: Grazoprevir has been administered to thousands of patients. Its toxicity profile is well-understood. Unlike experimental dimerizers (e.g., rimiducid) which require Phase I safety testing from scratch, the safety of GZV is established.

2. Specificity: HCV NS3 protease inhibitors are designed to target a viral enzyme that has no structural homolog in the human proteome. This "orthogonality" suggests that GZV treatment should have minimal off-target effects on the T-cell's own machinery or the patient's other tissues. This contrasts with Lenalidomide, which targets Cereblon, a native human protein involved in ubiquitination, potentially causing broader side effects (e.g., teratogenicity).³

3. Availability: As an FDA-approved drug, the manufacturing supply chain for GZV already exists.

4.3 Alternative Inhibitors and the "Switchboard"

The VIPER system is not limited to Grazoprevir. The HCV NS3 protease is the target of a large family of drugs, including:

• Danoprevir (DNV)

• Simeprevir

• Asunaprevir

• Glecaprevir

• Boceprevir

This chemical diversity is not merely redundant; it is functional. Different drugs have different binding footprints on the protease. The Wong lab exploited this to create "Switchboard" architectures. By mutating the NS3 domain or using different "reader" proteins that recognize specific drug-protease complexes, they engineered CARs that respond differently to different drugs.

• Example: A Switchboard CAR might target Antigen A in the presence of Grazoprevir but switch to targeting Antigen B in the presence of Danoprevir. This provides a solution to antigen escape (discussed in Section 8).²

5. In Vivo Performance and Efficacy Data

The transition from the petri dish to the living organism is the "valley of death" for many synthetic biology tools. The VIPER system, however, demonstrated robust efficacy in murine models.

5.1 The Xenograft Leukemia Model

The researchers utilized a standard stress test for CAR T-cells: the Nalm6 xenograft model. Nalm6 is a human B-cell acute lymphoblastic leukemia (ALL) cell line that expresses CD19.

• Experimental Design: Immunodeficient (NSG) mice were injected with luciferase-expressing Nalm6 cells. After tumor establishment, mice were treated with human T-cells transduced with the ON-VIPER CAR (anti-CD19).

• Treatment Arms:

• ON-VIPER CAR + Vehicle (No Drug).

• ON-VIPER CAR + Grazoprevir (daily injection).

• Constitutive CAR (Positive Control).

• Untransduced T-cells (Negative Control).

5.2 Results: Tumor Clearance and Survival

The data, as reported in Cancer Cell and summarized in the snippets, was definitive:

• Drug Dependency: Mice in the "No Drug" group (Arm 1) showed rapid tumor progression, indistinguishable from the negative control. This confirmed that the ON-VIPER CAR is essentially inert without the drug—a crucial safety validation.

• Efficacy: Mice in the Grazoprevir group (Arm 2) showed complete tumor regression. The kinetics of clearance mirrored the constitutive CAR, indicating that the drug-stabilized VIPER CAR is fully potent.

• Survival: At the 49-day endpoint, the Grazoprevir-treated group had 100% survival, whereas the untreated and negative control groups had 0% survival.

• Dosage: The study found that a dose of 50 mg/kg of GZV was effective for complete clearance. A lower dose of 25 mg/kg was also tested, showing the potential for dose-titration.²

5.3 Reversibility and Safety in CRS Models

To test the "off-switch" capability in a safety context, the team utilized a model of Cytokine Release Syndrome (CRS). In this model, high tumor burden and high T-cell doses induce a lethal cytokine storm.

• The Rescue: Mice treated with VIPER CARs + GZV began to exhibit signs of toxicity (weight loss, high cytokines). Upon cessation of GZV administration, the symptoms rapidly resolved. Serum cytokine levels (IL-6, IFN-Γ) dropped precipitously as the CARs self-cleaved and deactivated. The mice recovered, whereas mice with constitutive CARs (which cannot be turned off) succumbed to the toxicity. This provides in vivo proof that withdrawing the drug can save the subject from lethal immune overactivation.¹

6. Advanced Logic: Multiplexing and Orthogonality

One of the most powerful attributes of the VIPER system is its ability to play nice with others. In the complex microenvironment of solid tumors, a single antigen is rarely sufficient for cure. "Multiplexing"—targeting multiple antigens—is required.

6.1 Orthogonality with Lenalidomide

A key experiment in the Li et al. paper was demonstrating orthogonality. Could a Grazoprevir-gated CAR and a Lenalidomide-gated CAR function independently in the same animal?

• Setup: The researchers engineered T-cells expressing two different CARs controlled by two different mechanisms.

• CAR A (VIPER): Anti-Antigen A, gated by Grazoprevir.

• CAR B (Len-CAR): Anti-Antigen B, gated by Lenalidomide.

• Result:

• Adding GZV triggered killing of Tumor A but not Tumor B.

• Adding Lenalidomide triggered killing of Tumor B but not Tumor A.

• Adding both drugs cleared both tumors.

• Implication: This allows for precise Boolean logic. For example, a clinician could treat a patient with GZV to attack CD19. If the tumor relapses as CD19-negative/CD22-positive, they could switch to Lenalidomide to activate the anti-CD22 CAR, without needing a new infusion of cells.¹

6.2 The SUPRA-VIPER Integration

The Wong lab has also pioneered the SUPRA CAR system. SUPRA separates the antigen-binding portion (scFv) from the signaling portion (universal CAR) using a leucine zipper interface.

• Integration: By combining VIPER with SUPRA, the team created a "Universal ON-OFF" system. The VIPER mechanism gates the expression or stability of the universal signaling receiver (zipCAR).

• Benefit: This combines the flexibility of SUPRA (you can change the target by injecting a different adapter protein) with the safety of VIPER (you can turn the whole system off by stopping GZV). This represents the pinnacle of current CAR engineering: a T-cell that is both target-programmable and activity-programmable.⁵

6.3 The Switchboard CAR: Solving Antigen Escape

Antigen escape is a major cause of failure in CAR T-therapy (e.g., CD19-negative relapse in leukemia). The Switchboard CAR uses the NS3 protease to create a multi-input system.

• Mechanism: The NS3 domain interacts with different "reader" domains depending on which drug is bound to it.

• Input 1 (Grazoprevir): The NS3-GZV complex recruits Reader A, which is linked to scFv-A (e.g., anti-CD19).

• Input 2 (Danoprevir): The NS3-DNV complex recruits Reader B, which is linked to scFv-B (e.g., anti-CD22).

• Clinical Utility: A patient is treated with GZV. The T-cells kill CD19+ cells. The tumor mutates and loses CD19. The doctor stops GZV and starts Danoprevir. The same T-cells now reconfigure to target CD22. This adaptable therapy could prevent relapse without re-hospitalization or re-manufacturing.¹²

7. Nomenclature Clarification: Academic vs. Commercial

In the rapidly commercializing field of cell therapy, naming collisions are common. It is imperative to distinguish between the technology described above and the commercial entity "VIPER-101."

7.1 The BU Academic Platform (VIPER)

• Source: Wilson Wong Lab, Boston University.

• Mechanism: Versatile Protease Regulatable. Uses HCV NS3 protease and antiviral drugs for ON/OFF gating.

• Status: Preclinical (Mouse models).

• Key Paper: Cancer Cell 2022 (Li et al.).

7.2 The Vittoria Biotherapeutics Product (VIPER-101)

• Source: Vittoria Biotherapeutics (a Penn spin-out, though linked to the broader gene therapy ecosystem).

• Mechanism: Uses the Senza5™ platform. This mechanism is not protease gating. Instead, it involves the genetic deletion of CD5 (CD5 knockout) in the CAR T-cells to prevent "fratricide" (T-cells killing each other) and to enhance performance, coupled with an anti-CD5 CAR for treating T-cell lymphoma.

• Status: Clinical Phase 1 (NCT06420089).

• Acronym: In this context, VIPER likely stands for a proprietary internal designation unrelated to "Protease Regulatable" or is simply a brand name.

• Clarification: Users searching for "VIPER CAR" will find both. The protease switch is a synthetic biology tool for regulation. VIPER-101 is a specific therapeutic product for T-cell lymphoma focusing on CD5 editing. This report focuses on the BU Protease platform, but acknowledges VIPER-101 to prevent confusion.¹⁵

Table 2: Distinction Between VIPER Architectures

Feature	BU VIPER (Wong Lab)	VIPER-101 (Vittoria Bio)
Primary Mechanism	Drug-Gated ON/OFF Switch	CD5-Knockout + Anti-CD5 CAR
Key Component	HCV NS3 Viral Protease	Senza5™ Platform (Gene Editing)
Control Agent	Grazoprevir (Antiviral Drug)	Constitutive (Always On)
Primary Indication	Platform Technology (Tested in Leukemia)	T-Cell Lymphoma (TCL)
Development Stage	Preclinical / Academic Research	Phase 1 Clinical Trial

8. Limitations and Future Barriers

Despite its elegance, the VIPER protease system faces hurdles before it can reach patients.

8.1 Immunogenicity: The Viral Problem

The most glaring issue is the origin of the components. NS3 is a viral protein. Even though HCV is a chronic virus that evades immunity, placing a viral protein on the surface of a T-cell in a patient with a competent immune system creates a target.

• Rejection: The patient's immune system may generate cytotoxic T-cells (CTLs) against the NS3 peptides presented on the CAR T-cell's MHC molecules. This would lead to the destruction of the CAR T-cells, rendering the therapy ineffective.

• Mitigation: The snippet suggests that lymphodepletion (chemotherapy given before CAR T infusion) can delay this rejection. However, for long-term persistence (months to years), the immunogenicity of the protease is a significant liability compared to fully humanized switches.⁵

8.2 Complexity and Manufacturing

Adding a protease domain increases the size of the CAR gene. Lentiviral vectors, the delivery trucks of gene therapy, have a limited payload capacity.

• Titer: Larger genes often result in lower viral titers during manufacturing, making the production of the CAR T-cells more expensive and difficult.

• Gene Circuits: As the Wong lab adds more gates (AND gates, Switchboards), the genetic payload grows. Moving from "one gene, one protein" to "multi-gene circuits" is a major manufacturing challenge for the industry.³

8.3 Drug Cost and Compliance

While repurposing Grazoprevir is cheaper than developing a new drug, these antivirals are not free. Zepatier can cost thousands of dollars per course. However, in the context of a 400,000 CAR T-therapy, this cost is negligible. A bigger concern is patient compliance—the safety of the ON-switch depends on the patient reliably taking their pills every day.

9. Conclusion: A New Era of Programmable Medicine

The development of VIPER CAR T-cells by the Boston University team marks a maturing of synthetic biology. We are moving past the era of simply "redirecting" T-cells and entering an era of "programming" them.

The VIPER system validates several key principles:

1. Viral Repurposing: We can co-opt the machinery of pathogens (like HCV) to control therapeutic cells.

2. Chemical Biology: We can use clinically safe drugs to interface with biological hardware.

3. Fail-Safe Design: The shift to "default-OFF" architectures provides a necessary safety net for the testing of more potent, aggressive CAR designs.

While the immunogenicity of the viral protease remains a hurdle to be cleared—perhaps through computational de-immunization or the discovery of human protease analogues—the logic of the system is sound. By coupling the potency of the T-cell with the temporal precision of a pharmaceutical, VIPER CARs represent a glimpse into the future of oncology, where treatments are not just administered, but dynamically managed, tuned, and optimized in real-time.

As research continues, we anticipate the integration of VIPER-like switches into "4th Generation" CARs, creating cells that can sense their environment, perform logic operations, and respond to clinician commands, ultimately turning the tide against the most recalcitrant solid tumors.

Glossary of Key Terms:

• Chimeric Antigen Receptor (CAR): A synthetic receptor that redirects T-cells to identify and kill cancer cells.

• NS3 Protease: A viral enzyme from Hepatitis C Virus used in VIPER as the control switch.

• Grazoprevir: An FDA-approved antiviral drug that inhibits NS3, used here to turn the CAR "ON."

• Cis-Cleavage: The ability of an enzyme to cut the protein chain it is part of.

• Xenograft: A model where human tumor cells are grown in a mouse to test therapies.

• Orthogonality: The ability of two biological systems (e.g., two different CARs) to operate in the same cell without interfering with each other.

• Bioluminescence Imaging (BLI): A technique using luciferase to track tumor size in live mice.

• Senza5: A separate technology platform by Vittoria Biotherapeutics involving CD5 deletion, used in the clinical VIPER-101 product.

Works cited

1. High-performance multiplex drug-gated CAR circuits - PubMed - NIH, accessed January 3, 2026, https://pubmed.ncbi.nlm.nih.gov/36084652/

2. Immune cells engineered to battle cancer can be turned “on” or “off ..., accessed January 3, 2026, https://www.eurekalert.org/news-releases/964332

3. High-performance multiplex drug-gated CAR circuits | Request PDF - ResearchGate, accessed January 3, 2026, https://www.researchgate.net/publication/363386214_High-performance_multiplex_drug-gated_CAR_circuits

4. High-performance multiplex drug-gated CAR circuits Spotlight - Accelerating Cancer Immunotherapy Research, accessed January 3, 2026, https://acir.org/journal-articles/experimental-immunotherapy/immunotherapy-design?entryId=62952

5. High-performance multiplex drug gated CAR circuits - PMC - PubMed Central - NIH, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9669166/

6. (PDF) Harnessing Viral Proteases for Cellular and Molecular Engineering - ResearchGate, accessed January 3, 2026, https://www.researchgate.net/publication/391021529_Harnessing_Viral_Proteases_for_Cellular_and_Molecular_Engineering

7. Immune Cells Engineered to Battle Cancer Can Be Turned “On” or ..., accessed January 3, 2026, https://www.bu.edu/articles/2022/immune-cells-engineered-to-battle-cancer-can-be-turned-on-or-off/

8. Small-molecule control of CAR T cells - PMC - PubMed Central, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12746335/

9. Intelligent tunable CAR-T cell therapy leads the new trend - PMC, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10518343/

10. Artificial Targets: a versatile cell-free platform to characterize CAR T cell function in vitro - Frontiers, accessed January 3, 2026, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1254162/full

11. accessed January 3, 2026, https://www.technologynetworks.com/cancer-research/news/car-t-cell-onoff-switch-may-make-treatments-safer-and-more-effective-365569#:~:text=Their%20new%20system%20is%20called,that%20come%20with%20traditional%20CARs.

12. Engineering clinically-approved drug gated CAR circuits - bioRxiv, accessed January 3, 2026, https://www.biorxiv.org/content/10.1101/2020.12.14.419812v1.full.pdf

13. High-performance multiplex drug-gated CAR circuits: Cancer Cell, accessed January 3, 2026, https://www.cell.com/cancer-cell/fulltext/S1535-6108(22)00372-5

14. Engineering clinically-approved drug gated CAR circuits | bioRxiv, accessed January 3, 2026, https://www.biorxiv.org/content/10.1101/2020.12.14.419812.full

15. Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting Supporting its Novel Approach to Engineered CAR-T Cell Therapies, accessed January 3, 2026, https://vittoriabio.com/news/vittoria-biotherapeutics-presents-positive-preclinical-data-at-66th-annual-ash-meeting-supporting-its-novel-approach-to-engineered-car-t-cell-therapies/

16. ViTToria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of its VIPER-101 T-Cell Therapy - Penn Center for Innovation, accessed January 3, 2026, https://pci.upenn.edu/vittoria-biotherapeutics-announces-dosing-of-first-patient-in-phase-1-clinical-trial-of-its-viper-101-t-cell-therapy/

17. Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma, accessed January 3, 2026, https://vittoriabio.com/news/vittoria-biotherapeutics-announces-fda-clearance-of-ind-application-for-viper-101-to-treat-t-cell-lymphoma/

18. Advancing CAR-T therapy: how CD5 modulation is shaping cancer treatment, accessed January 3, 2026, https://www.drugtargetreview.com/article/152387/advancing-car-t-therapy-how-cd5-modulation-is-shaping-cancer-treatment/